Leonid Tamesha

Leonid Tamesha inquired about the depth of BRINSUPRI prescribing, noting that many physicians have written only one script. He asked what factors might be causing this, what additional education efforts are underway, and the progress of the drug through P&T committees in academic centers.

Answer

Will Lewis, Chair and CEO, explained that it is typical for physicians to initially try a new medicine on one or two patients. He anticipates that positive patient experiences, expected to be reported back in Q1 and Q2, will drive broader prescribing. He highlighted the existence of a broad prescribing base and the activation of an extensive speakers bureau and other programs to provide peer-to-peer education and reinforce positive experiences.